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longer disease duration (0.96; 0.94, 0.98) and worse HAQ (0.74; 0.60, 0.92). Social 
functioning improved with better VASQOL (8.62; 3.32, 13.91), but worsened with 
more comorbidities (−0.92; −1.49, −0.35), anxiolytic and/or antidepressant use (−5.33; 
−7.68, −2.98), worse RADAI (−1.54; −2.80, −0.28), HAQ (−8.38; −10.51, −6.25) and 
fatigue (−1.06; −1.48, −0.65). Furthermore, the mechanism by which RADAI affected 
social functioning did not appear to be through pain (0.20; −0.43, 0.84), but through 
HAQ as it absorbed 56% of the explanatory power of RADAI. CONCLUSIONS: 
Performance of social roles was limited among RA patients with more HAQ disability, 
and improved by better quality of life. Disease activity appeared to inﬂ uence social 
functioning through worse physical disability but not through pain.
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BACKGROUND: Disease activity and disability should be assesssed at each rheuma-
toid arthritis (RA) patient visit to monitor response to therapy. Disease activity has 
been traditionally evaluated by the disease activity scale (DAS-28) and the ACR cri-
teria, which depend on physicians, but few studies have analyzed short-term predictors 
of the patient self-reported RA disease activity index-RADAI. Disability is routinely 
assessed by the health assessment questionnaire (HAQ) whose long term predictors, 
but not short-term, have been extensively studied. OBJECTIVES: To analyze whether 
the 6-month baseline levels of HAQ and of RADAI and other factors predict change 
at 6-month intervals. METHODS: RA patients from the biannual NDB-Portugal 
cohort were used. For each patient, differences between two consecutive 6-month 
intervals were computed for HAQ (0–3, 3 is worse) and RADAI (0–10, 10 is worse). 
For each scale, a binary outcome was constructed based upon these differences, where 
a positive increment meant worsening in function and disease activity. Patients’ obser-
vations whose increments were null were excluded. Univariate (UV) and multivariate 
(MV) generalized estimating equations were used. Factors included age, sex, marital 
status, disease duration, education level, number of major comorbidities, paid work 
status and 6-month baseline HAQ and RADAI levels. RESULTS: MV analyses 
revealed that the main predictors of HAQ were baseline HAQ: (OR: 0.49, 95% CI 
0.44, 0.54), number of comorbidities (1.09 (1.05, 1.14)), and age (1.02 (1.01, 1.02)); 
For RADAI they were, baseline RADAI (0.69 (0.66, 0.73)), comborbidities (1.11 
(1.07, 1.16)), and educational level (0.95 (0.93, 0.97)). CONCLUSIONS: Worse 
baseline levels of HAQ and RADAI predicted their respective improvement 6-months 
later. This could be due to optimization of treatment strategies when worse baseline 
scores are detected, but whatever the reason, performing these two patient reported 
outcomes are a quick and non-rheumatologist dependent way to improve patients’ 
disease status over 6-month intervals.
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USE OF PATIENT-REPORTED OUTCOMES IN ON-LINE COMMUNITIES 
TO CONDUCT OBSERVATIONAL COMPARATIVE EFFECTIVENESS 
RESEARCH: A PILOT STUDY IN RHEUMATOID ARTHRITIS
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OBJECTIVES: The demand for comparative effectiveness research (CER) data from 
payers, physicians, and patients is signiﬁ cant, but the cost and time associated with 
prospective randomized trials is a barrier to rapid decision-making. Use of patient-
reported outcomes (PROs) collected via on-line patient communities provides one 
channel for rapid data collection, particularly in conditions such as rheumatoid arthri-
tis (RA), where validated PRO instruments are available. METHODS: A random 
sample of iGuard.org members in the US treated with non-steroidal anti-inﬂ ammatory 
drug (NSAIDs), oral disease-modifying antirheumatic drugs (DMARDs), or biologics 
for RA completed the Rheumatoid Arthritis Disease Activity Index (RADAI) and a series 
of other questions related to their disease. iGuard.org is a free medication monitoring 
service that is introduced to patients through multiple sources including physician, 
pharmacy and online referrals. For this study, we report pilot baseline data on patient-
reported RADAI, pain, and joint counts across the three treatment groups to demon-
strate use of on-line communities in supporting CER. RESULTS: A total of 153 RA 
patients completed the study: 49 treated with NSAIDs only, 51 exposed to oral 
DMARDs, and 53 exposed to biologics. The mean (SD) RADAI score was 4.59 (2.16). 
Adjusting for age and gender and multiple comparisons, there were signiﬁ cant differ-
ences between the three treatment groups on RADAI scores (p = 0.0045) and patient 
global assessment of pain (p = 0.0357) but not on the number of painful joints (p = 
0.3512). The trend was towards patients on NSAIDs only having worse outcomes 
compared to patients on biologics or patients on oral DMARDs. CONCLUSIONS: 
This pilot study demonstrates the possibility of collecting baseline disease severity data 
directly from patients using the RADAI, which is sensitive to detect differences by 
treatment modality. The next step in the pilot program will be to investigate the 
potential for capturing longitudinal disease progress information amongst patients in 
on-line communities. 
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: To examine the pattern of palivizumab utilization and compliance in 
infants with pre-existing disease within the Canadian Registry Database (CARESS). 
METHODS: A prospective, registry of infants across 27 sites who received at least 1 
dose of palivizumab during the 2006–2009 RSV seasons. Neonatal and demographic 
data were collected from the parent/caregiver at enrollment. Data on palivizumab 
utilization, compliance, and outcomes related to respiratory illness (RI) events were 
collected monthly. Premature infants ≤35 completed weeks gestational age without 
medical conditions who met standard approval criteria for palivizumab (Group 1) 
were compared to those with underlying medical disorders who received prophylaxis 
(Group 2). RESULTS: Group 1 (n = 3379) Group 2 (n = 489). Male: 56.8% versus 
54.6% (P = 0.433). Average Enrollment Age (months) ± SD: 3.6 ± 3.4 versus 9.9 ± 
8.8 (P = 0.000). Average GA (weeks) Mean ± SD: 31.0 ± 3.1 versus 37.1 ± 4.3 (P = 
0.000). Average # injections ± SD: 3.6 ± 1.5 versus 3.7 ± 1.5 (P = 0.159). Hospitaliza-
tion Rate (HR) for RI: 4.1% versus 9.2% (P = 0.000). RSV HR: 1.3% versus 2.7% 
(P < 0.05). On average infants received 86.0% ± 28.3% of the expected number of 
injections. Group 2 infants comprised Down syndrome (n = 118, 24.1%), upper 
airway anomalies (n = 112, 22.9%), cystic ﬁ brosis (n = 62, 12.7%), neuromuscular 
impairment (n = 42, 8.6%), pulmonary (n = 38, 7.8%), multiple system disorders (n 
= 34, 7.0%), cardiac (n = 17, 3.5%), immunocompromise (n = 8, 1.6%), and miscel-
laneous (n = 58, 11.9%). From 2006–2009, the proportion of Group 2 infants receiv-
ing prophylaxis increased 2-fold from 5.6% (69/1224) to12.2% (245/2016). Overall. 
Group 2 infants were older at enrollment with more advanced GA and had signiﬁ -
cantly higher RI and RSV hospitalization rates. No serious adverse events directly 
related to palivizumab occurred. CONCLUSIONS: Results imply that infants with 
underlying medical disorders that are not approved for prophylaxis by advisory bodies 
and current position statements are at greater risk for RSV infections and 
hospitalization.
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OBJECTIVES: Palivizumab is used for respiratory syncytial virus (RSV) prophylaxis 
in high risk children. Data on seasonality, risk factors, and outcomes are necessary to 
evaluate the impact of palivizumab on the incidence of RSV infections, minimize health 
care resources and identify which infant sub-sets are receiving prophylaxis.To deter-
mine current usage of palivizumab prophylaxis, compliance patterns, hospitalization 
rate (HR) and outcomes in children at high-risk of respiratory syncytial virus (RSV) 
infection through a Canadian Registry Database (CARESS). METHODS: A prospec-
tive, study of infants who received at least 1 dose of palivizumab in the 2006–2009 
RSV seasons across 27 sites. Neonatal and demographic data were collected upon 
enrolment. Parents/caregivers were contacted monthly for data on palivizumab utiliza-
tion, compliance and outcomes related to any respiratory tract events. RESULTS: A 
total of 4926 infants aged 2 days–47 months (mean = 5.4 months) were enrolled. 
Participants were typically male (57.1%) and Caucasian (70.8%). Gestational age 
(GA) was 32.2 ± 4.6 completed weeks. 3480 (70.6%) premature infants received 
palivizumab (≤35 completed weeks GA), 403 (8.2%) required O2, 471 (9.6%) had 
congenital heart disease and 572 (11.6%) were prophylaxed for other risk factors. On 
average patients received 3.7 ± 1.5 injections, with 17,982 doses given overall. There 
were no drug related serious adverse events.296 infants required 357 hospitalizations 
for respiratory tract infections with a hospitalization rate of 6.0%. There were signiﬁ -
cant differences between indications for palivizumab (chi-square = 71.8, P < 0.005).
The overall RSV positive HR was 1.38%. Hospitalization rates were highest in infants 
of aboriginal descent (15.0%, chi-square = 22.2, P < 0.005). Hospitalized infants had 
a lower percentage of compliant injections (62.8% versus 68.6%, p = 0.003). CON-
CLUSIONS: The RSV HR in the 2006–2009 RSV seasons resembled several published 
reports (range 1.3%–5.3%). RSV HR may be decreasing because of compliance with 
palivizumab prophylaxis, variability in RSV epidemiology, hospital admission criteria 
and preventive education.
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OBJECTIVES: Comorbidity is an important factor in any comparative assessment of 
treatments associated with morbidity and mortality of patients. Many factor such as 
age, gender and duration of a disease can inﬂ uence the impact of comorbid diseases 
on quality of life. In the health care setting (the primary source of data for most 
observational studies), the decision to give a particular treatment to a particular 
patient with a given disease is generally based on patient speciﬁ c characteristics, the 
most important of which is disease condition. Thus, confounding by indication/disease 
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severity is a common source of bias. Consequently, failure to properly control for the 
bias could lead to serious ﬂ aws in the study. METHODS: We used a novel approach 
for identifying comorbidities associated with COPD by mapping the incident comor-
bidity patterns in the pre-COPD diagnosis period as well as over the course of the 
disease using a retrospective cohort of patients aged 50+ in the UK General Practice 
Research Database. Each patient was matched to another without COPD on year of 
birth, sex, general practice and completed years of medical records up to at least a 
year after the index date for COPD between 1990 and 1998. We identiﬁ ed 24,000 
such pairs that also satisﬁ ed a requirement for at least one medical consultation and 
at least one prescription for any drug in the year prior to the index date for COPD. 
RESULTS: Based on trends in rate ratios, we found signiﬁ cant time-dependent associa-
tions between the incident COPD diagnosis and incident comorbid conditions such as 
lung cancer, myocardial infarction, pneumonia, cardiac disorders, osteoporosis, frac-
tures, skin bruises, psychiatric disorders and respiratory infections. CONCLUSIONS: 
The results indicated interesting associations which could help improve our under-
standing of the natural history of COPD and its burden. This methodology can be 
used to identify important comorbidities for effective comparative assessments.
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OBJECTIVES: The objective of this study was to estimate the effectiveness of vareni-
cline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in two 
specialized smoking units belonging to primary care centers. METHODS: A multi-
center longitudinal observational study was designed. Patient’s data were collected 
retrospectively based on their clinical records. Patients over the age of 18, who initi-
ated treatment of smoking cessation between January 1, 2006 and January 12, 2008 
with varenicline, bupropion or NRT were included in the analysis. Patient’s follow-up 
was conducted from time-baseline (day 1) and assessed at 6 and 12 months. Main 
variables included in the study were: comorbidities, effectiveness (continuous absti-
nence) and pharmacological tolerability. Statistical analysis was performed by Kaplan-
Maier survival curves; P < 0.05. RESULTS: A total of 957 smokers patients treated 
with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the 
analysis. The mean age of participants was 47.6 (11.3) years and 58.6% were men. 
The average duration of smoking was 19.5 (6.7) years. At 6 months, 61.2% (95% 
CI: 54.6–67.8%) of participants in the varenicline group were continuously abstinent 
from smoking compared with 56.9% (95% CI: 50.6–63.2%) in the bupropion group 
and 52.3% (95% CI: 48.0–56.6%) in the NRT group; p = 0.003. At 12 months, the 
rate of continuous abstinence was 57.4% (95% CI: 50.7–64.1%) in the varenicline 
group compared with 52.9% (95% CI: 46.6–59.2%) in the bupropion group and 
47.1% (95% CI: 42.8–51.4%) in the NRT group; p = 0.002. Pharmacological toler-
ability was similar between groups except for symptoms of irritability which were 
lower in the varenicline group: 4.3% compared to 8.3% in the bupropion group and 
10.3% in the NRT group. CONCLUSIONS: Varenicline appeared to be an effective 
and safety alternative compared with bupropion and NRT on smoking cessation in 
the primary care setting.
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BUDESONIDE/FORMOTEROL PLUS TIOTROPIUM (BUD/FORM + TIO) VS. 
SALMETEROL/FLUTICASONE PLUS TIOTROPIUM (SALM/FLU + TIO): A 
SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON 
BETWEEN TWO ALTERNATIVE TRIPLE TREATMENTS IN CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (COPD)
Edwards SJ, Gray J
AstraZeneca UK Ltd, Luton, Bedfordshire, UK
OBJECTIVES: Use of triple therapy (long-acting beta2 agonist [LABA], inhaled corti-
costeroid [ICS] and long-acting muscarinic antagonist [LAMA]) for the treatment of 
COPD has doubled in the UK over the past 5 years for all severities of the disease. 
This research was designed to compare the two most commonly prescribed combina-
tion inhalers (BUD/FORM and SALM/FLU) as the basis of triple therapy with TIO, 
the most widely used LAMA. METHODS: Systematic review of CENTRAL, EMBASE 
and MEDLINE for randomised controlled trials (RCTs) in patients with COPD treated 
with BUD/FORM+TIO or SALM/FLU+TIO was conducted in May 2010. Mixed 
treatment comparison (MTC) using TIO as a common comparator was conducted 
using a Bayesian Markov Chain Monte Carlo simulation. Fixed- and random-effects 
models were explored with the preferred model selected based on the Deviance Infor-
mation Criterion (DIC). Data was extracted from relevant trials on severe exacerba-
tions (a composite of oral corticosteroids, hospitalizations and A&E visits due to 
worsening symptoms). Summary effect estimate was calculated as odds ratio (OR) 
with 95% credible interval (95% CrI) where OR < 1 favoured BUD/FORM+TIO and 
OR > 1 favoured SALM/FLU+TIO. RESULTS: Of the 124 papers identiﬁ ed in the 
literature search, 3 RCTs had comparable patient populations and were able to supply 
data for analysis (1 BUD/FORM+TIO [N = 660] and 2 SALM/FLU+TIO [N = 301 
and N = 60]). The exclusion of papers was based on not meeting all of the following 
inclusion critieria: RCTs of the chosen comparators; COPD patient population; 
reporting exacerbations; English-language full publication; and non-duplicates. When 
the ﬁ xed- and random-effects MTC models were compared the ﬁ xed-effects MTC had 
the lowest DIC. The results indicate a 55% relative reduction in severe exacerbations 
with BUD/FORM+TIO compared to SALM/FLU+TIO (OR 0.45, 95% CrI: 0.22 to 
0.83). CONCLUSIONS: This MTC suggests that BUD/FORM-based triple therapy is 
signiﬁ cantly more effective at reducing severe exacerbations than SALM/FLU-based 
triple therapy.
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OBJECTIVES: Modeling a chronic disease like COPD is useful to extrapolate (inter-
mediate) treatment effects observed in short-term randomized trials to the medium or 
long term. This study aimed to extend an existing dynamic population model of COPD 
progression by including exacerbations and making the model stochastic. METHODS: 
The COPD model starts with COPD prevalence in the Dutch population speciﬁ ed by 
age, gender, disease severity (four severity stages) and smoking status. Each following 
year the model simulates the changes in the prevalence and COPD-related health care 
costs due to incidence, mortality and disease progression, i.e. annual decline in FEV1% 
predicted.The structure was adjusted to include moderate and severe exacerbations 
and the following input parameters were estimated by quantitative meta-analyses: the 
frequency, case-fatality, lung function decline, quality of life loss and costs of exacerba-
tions. The model was made stochastic by specifying probability distributions around 
all important model parameters. The adapted model can be used to assess the impact 
of interventions that inﬂ uence COPD incidence, disease progression, frequency and/or 
severity of exacerbations, mortality, quality of life or combinations of these effects. To 
illustrate the potential use of the model, long- term costs and effects were projected 
for four different COPD interventions, two on pharmacotherapy, one on smoking 
cessation therapy and one on pulmonary rehabilitation. RESULTS: Compared to a 
reference scenario representing minimal treatment, the cost-effectiveness of the four 
interventions ranged from c6,100 to c12,200 per QALY gained. The probability of 
the interventions to be cost-effective at a ceiling ratio of c20,000 varied from X to 
Y%. CONCLUSIONS: The extended COPD model can provide policy makers with 
information about long-term costs and effects of interventions over the entire chain, 
from primary prevention to care for very severe COPD. Moreover it describes the 
uncertainty of the outcomes.
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A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF 
CICLESONIDE WITH FLUTICASONE IN 1:1 AND 1:2 DOSE RATIOS IN 
THE TREATMENT OF BRONCHIAL ASTHMA
Wojciechowski P, Stozek A, Rogoz A, Rys P, Wladysiuk M, Plisko R
HTA Consulting, Krakow, Poland
OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
ﬂ uticasone (FP) in the treatment of bronchial asthma. METHODS: Comparison was 
based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Ten RCTs directly 
comparing CIC vs. FP were identiﬁ ed and included in the analysis. Comparisons of 
both interventions in 1:1 and 1:2 dose ratios were assessed in 8 and 5 trials, respec-
tively. Efﬁ cacy of CIC was comparable to FP in both, 1:1 and 1:2 dose ratios with 
respect to reduction in risk of asthma exacerbations, improvement in proportion of 
symptom-free days, rescue medication-free days and improvement in asthma symp-
toms. Moreover, CIC and FP showed similar improvement in spirometric parameters. 
Comparison between CIC and FP in 1:1 dose ratio revealed that treatment with CIC 
was associated with statistically signiﬁ cant risk reduction of adverse events possibly 
related to study medication (RR = 0.57 [0.39; 0.83]; NNT = 16.89 [10.24; 48.18]) 
and candidosis (RR = 0.31 [0.17; 0.56], NNT = 32.74 [22.23; 61.99]), while the 
differences between groups were not signiﬁ cant for 1:2 dose ratio. There were no 
statistically signiﬁ cant differences between CIC and FP in either dose ratio with respect 
to the risk of any adverse events, upper respiratory tract infections, pharyngitis and 
dysphonia. CONCLUSIONS: Ciclesonide is a therapeutic option for patients with 
bronchial asthma showing comparable efﬁ cacy to ﬂ uticasone in both 1:1 and 1:2 dose 
ratios and provides concomitant risk reduction of candidosis and adverse events 
related to study medication.
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Wojciechowski P, Stozek A, Rogoz A, Rys P, Wladysiuk M, Plisko R
HTA Consulting, Krakow, Poland
OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
budesonide (BUD) in the treatment of bronchial asthma. METHODS: Comparison 
was based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
